# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-22-006618
Filing Date
2022-03-11
Accepted
2022-03-11 16:05:37
Documents
56
Period of Report
2022-01-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 |  | form10-q.htm iXBRL | 10-Q | 1072483
2 |  | ex31-1.htm | EX-31.1 | 18096
3 |  | ex31-2.htm | EX-31.2 | 18546
4 |  | ex32-1.htm | EX-32.1 | 7576
5 |  | ex32-2.htm | EX-32.2 | 8010
| Complete submission text file | 0001493152-22-006618.txt |  | 5111652

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL SCHEMA FILE | anix-20220131.xsd | EX-101.SCH | 29076
7 | XBRL CALCULATION FILE | anix-20220131_cal.xml | EX-101.CAL | 38723
8 | XBRL DEFINITION FILE | anix-20220131_def.xml | EX-101.DEF | 125358
9 | XBRL LABEL FILE | anix-20220131_lab.xml | EX-101.LAB | 250146
10 | XBRL PRESENTATION FILE | anix-20220131_pre.xml | EX-101.PRE | 192458
50 | EXTRACTED XBRL INSTANCE DOCUMENT | form10-q_htm.xml | XML | 1100680

Mailing Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118
Business Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118 408-708-9808
Anixa Biosciences Inc (Filer) CIK: 0000715446 (see all company filings)

EIN.: 112622630 | State of Incorp.: DE | Fiscal Year End: 1031
Type: 10-Q | Act: 34 | File No.: 001-37492 | Film No.: 22733154
SIC: 2834 Pharmaceutical Preparations